Insights for all patient cohorts
ArteraAI Prostate Test is the first AI-powered test that can predict therapy benefit, help inform active surveillance decision-making, and prognosticate long-term outcomes in localized prostate cancer, as recommended in national guidelines.
Fast and convenient
Since the test inputs only require the digitized images of the patient’s biopsy slide and patient clinical information, test results can be shared within 24-36 hours after receipt of the patient’s biopsy specimen. There’s no tissue consumption or risk of insufficient tissue sample leading to inconclusive results.
Robust model validation
Multiple Phase 3 randomized trials with up to 15-year follow-up were used to develop and validate the prognostic and predictive MMAI models. The prognostic model has also been further validated across diverse patient populations and regardless of subsequent management options. Validation cohorts included patients who were managed with active surveillance, were treated with radiation therapy, or had a radical prostatectomy.
Roach M, et al. Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials. J Clin Oncol. 2022;40(16_suppl):108-108.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.108
Suitable for patients across all risk groups
The ArteraAI Prostate Test can be used for patients across all NCCN risk groups, with 10-year risk of distant metastasis (DM) and prostate cancer specific mortality (PCSM) reported and can be used to assess how aggressive the cancer is.
For lower-risk patientsFor patients with NCCN very low-, low-, or favorable intermediate-risk disease., the ArteraAI Prostate Test will also report the relative risk of adverse pathology (AP) at radical prostatectomy (RP) to help inform if active surveillance is a suitable management option.
For intermediate-risk patients, the ArteraAI Prostate Test can be used to predict if there will be a therapeutic benefit from adding ST-ADT to radiation therapy.
The ArteraAI Prostate Test is intended to assist clinicians with risk-based decisions in localized prostate cancer within recommended clinical treatment guidelines. This multimodal artificial intelligence (MMAI) test is recommended for patients with localized prostate cancer in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer*Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2025 © 2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
NCCN, National Comprehensive Cancer Network..
The science behind the ArteraAI Prostate Test
Artera’s multimodal artificial intelligence (MMAI) platform leverages a unique algorithm that assesses both the digital images from a patient’s biopsy and their clinical data. The AI combines this information to estimate long-term outcomes and predict whether a patient will benefit from hormone therapy.
The algorithm was developed using large datasets, from thousands of patients and tens of thousands of pathology slide images, and has been clinically validated using multiple Phase 3 randomized trials and in a variety of patient cohorts.
Test Guide
This test guide provides a comprehensive explanation of how the ArteraAI Prostate Test works, how it was validated, and how it can be used to help patients with localized prostate cancer.
Test Requisition Form
The test requisition form can be completed and faxed into Artera to order the ArteraAI Prostate Test for a patient. This form requires an ordering clinician signature.
Sales Brochure
This brochure explains what the ArteraAI Prostate Test is intended for use, along with the various benefits such as fast turnaround time and lack of tissue consumption.
Sample Test Report
These are sample test reports to show what the ArteraAI Prostate Test results would look like for patients in different categories of NCCN risk groups.
Ordering is Easy with Artera
The ArteraAI Prostate Test is a laboratory-developed testTesting is performed by ArteraAI, located at 6800 Southpoint Pkwy Suite 950, Jacksonville, Florida 32216. The ArteraAI Prostate Test was developed and its performance characteristics were determined by ArteraAI. This Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) as qualified to perform high-complexity clinical laboratory testing. This test is used for clinical purposes and should not be regarded as investigational or for research. This test has not been cleared or approved by the U.S. Food and Drug Administration. that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL.
-
The ArteraAI Prostate Test is intended for adult males 18 years of age or older with localized prostate cancer, without clinically or pathologically defined metastases. The intended patient should also be a candidate for curative intent management (surgery, radiation therapy ± systemic therapy, or active surveillance).
-
Yes! You can visit the ArteraAI Test Report page to explore each section of the report to better understand the results.
-
Currently, Artera cannot accept orders from New York. Artera is actively pursuing New York licensing and will provide future updates to its certification status.
-
After you reach out to us, a member of our Customer Success team will set up an account in the ArteraAI Portal to enable order submission.
-
No. Ordering of the ArteraAI Prostate Test is limited to clinicians whose license and scope of practice allows them to order the test. However, we encourage patients to share information about ArteraAI with their doctor.
-
Using the ArteraAI Prostate Test, results can be shared within 24-36 hours after receipt of the patient’s specimen.
-
The out-of-pocket cost for the ArteraAI Prostate Test will be based on the patient’s insurance plan. If the patient is covered by Medicare Plan B, they should have zero out-of-pocket costs for the ArteraAI Prostate Test. If the patient is covered by private insurance, financial liability will be subject to the terms of their plan taking into consideration copays, coinsurance and deductibles. Patients should contact billing@artera.ai for additional questions about their estimated out-of-pocket liability for the test.